Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GALNT14 gene

Known as: UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE:POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE 14, polypeptide N-acetylgalactosaminyltransferase 14, polypeptide GalNAc transferase 14 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
N-Acetylgalactosaminyltransferase-14 (GALNT14) is a member of acetylgalactosaminyltransferases family. We have shown that GALNT14… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2016
2016
Some polypeptide N-acetyl-galactosaminyltransferases (GALNTs) are associated with cancer, but their function in organ-specific… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2016
2016
Increasing evidence has suggested that dysregulation of microRNAs (miRNAs) could contribute to tumor progression. The miR-125a… Expand
2016
2016
AIM Transcatheter arterial chemoembolization is currently the standard treatment in hepatocellular carcinoma patients with… Expand
2015
2015
Although several genes have been associated to neuroblastoma (NB) predisposition and aggressiveness, further genes are likely… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
2015
2015
Aberrant glycosylation is a hallmark of most human cancers and affects many cellular properties, including cell proliferation… Expand
2014
2014
A GALNT14 single nucleotide polymorphism, rs9679162, has recently been found to be capable of predicting chemotherapy responses… Expand
  • table I
  • table II
  • figure 1
  • table III
  • figure 2
2013
2013
A high expression of O-glycosylated proteins is one of the prominent characteristics of ovarian carcinoma cells associated with… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2011
2011
AIM Despite the availability of targeted anticancer agents, combination chemotherapy remains an option for patients with far… Expand
2010
2010
Purpose: In vitro sensitivity to the proapoptotic receptor agonists dulanermin (rhApo2L/TRAIL) and drozitumab (DR5-agonist… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5